Research Topics
| H HasleSummaryAffiliation: University of Copenhagen Country: Denmark Publications
| Collaborators
|
Detail Information
Publications
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseasesH Hasle
Department of Pediatrics, Skejby Hospital, Aarhus, Denmark
Leukemia 17:277-82. 2003..Cytogenetics and serial assessments of the patients are essential adjuncts to morphology both in diagnosis and classification...
Myelodysplastic and myeloproliferative disorders in childrenHenrik Hasle
Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
Curr Opin Pediatr 19:1-8. 2007..A number of significant advances have been achieved in recent years. The present review will focus on diagnostics and therapy...
Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004Henrik Hasle
Department of Pediatrics, Aarhus University Hospital, Skejby, Denmark
Blood 120:978-84. 2012..In conclusion, GO therapy postconsolidation as given in this trial was well tolerated, showed a nonsignificant delay in time to relapse, but did not change the rate of relapse or survival (clinicaltrials.gov identifier NCT00476541)...
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective studyHenrik Hasle
Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
Blood 109:4641-7. 2007..Childhood AML with chromosome 7 aberrations represents a heterogeneous group of disorders with additional cytogenetic aberrations having a major prognostic impact which should be reflected in future risk-group stratification...
Malignant diseases in Noonan syndrome and related disordersHenrik Hasle
Department of Pediatrics, Aarhus University Hospital Skejby, Denmark
Horm Res 72:8-14. 2009..Registry-based studies of patients with NS and related disorders diagnosed with molecular genetics and a high-quality long-term follow-up are necessary to further estimate the incidence of malignancy...
Pattern of malignant disorders in individuals with Down's syndromeH Hasle
Department of Paediatrics, Skejby Hospital, Aarhus University, Denmark
Lancet Oncol 2:429-36. 2001..Increased susceptibility to apoptosis in DS may result in cell death rather than malignant transformation after major cell injuries. This hypothesis would explain the decreased risk of both solid tumours and secondary cancers...
[Occurrence of cancer in individuals with Down syndrome]H Hasle
Arhus Universitetshospital, Skejby Sygehus
Ugeskr Laeger 162:4535-9. 2000..The distinctive pattern of malignancies may provide clues in the search for leukaemogenic genes and tumour suppressor genes on chromosome 21...
Advances in the prognostication and management of advanced MDS in childrenHenrik Hasle
Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
Br J Haematol 154:185-95. 2011..Intensive chemotherapy before HSCT should be considered in patients with myelodysplasia-related-AML (MDR-AML)...
The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)H Hasle
Department of Pediatrics, Skejby Hospital, Aarhus University, Denmark
Leukemia 18:2008-14. 2004..In conclusion, the IPSS is of limited value in both pediatric MDS and JMML. The results reflect the differences between myelodysplastic and myeloproliferative diseases in children and adults...
Treatment-related deaths in second complete remission in childhood acute myeloid leukaemiaLene Molgaard-Hansen
Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
Br J Haematol 152:623-30. 2011..Fourteen (82%) of 17 TRDs occurred in children undergoing haematopoietic stem cell transplantations (HSCT). Optimal supportive care after HSCT is essential, and studies on risk factors for TRD are needed...
Risks of leukaemia and solid tumours in individuals with Down's syndromeH Hasle
Department of Paediatrics, Aarhus University Hospital Skejby, Denmark
Lancet 355:165-9. 2000..Individuals with Down's syndrome have a greater risk of leukaemia than the general population, but reliable estimates of the age-specific risk are lacking and little is known about the risk of solid tumours...
Occurrence of cancer in women with Turner syndromeH Hasle
Department of Paediatrics, Odense University Hospital, Denmark
Br J Cancer 73:1156-9. 1996..Colon cancer was observed in five patients (relative risk 6.9, 95% confidence interval 2.2-16.2). Further studies are needed to assess whether colon cancer in TS is related to Turner-associated genes on the sex chromosome(s)...
Evidence of decreased risk of cancer in individuals with fragile XS Schultz-Pedersen
Department of Pediatrics, Viborg Hospital, Viborg, Denmark
Am J Med Genet 103:226-30. 2001..28 (95% confidence interval: 0.1-0.8). The possibility that the expanded trinucleotide repeats in fragile X syndrome protect against cancer is discussed...
Cancer incidence in men with Klinefelter syndromeH Hasle
Department of Paediatrics, Odense University Hospital, Denmark
Br J Cancer 71:416-20. 1995..The overall cancer incidence is not increased and no routine cancer screening seems to be justified. A considerably elevated risk of mediastinal germ cell tumours occurs in the period from early adolescence until the age of 30...
A population-based study of childhood myelodysplastic syndrome in British Columbia, CanadaH Hasle
Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
Br J Haematol 106:1027-32. 1999..Data on MDS from treatment-based studies and cancer registries were inaccurate and seemed to significantly underestimate the incidence of MDS in children...
Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003Lene Molgaard-Hansen
Department of Paediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
Br J Haematol 151:447-59. 2010..The number of EDs and TRDs in AML is high. Therefore optimal antifungal prophylaxis is essential, and studies on the benefit of antibacterial prophylaxis and individual risk factors for ED and TRD are needed...
Improved outcome after relapse in children with acute myeloid leukaemiaJonas Abrahamsson
Department of Clinical Sciences, Queen Silvia s Childrens Hospital, Gothenburg, Sweden
Br J Haematol 136:229-236. 2007..A significant proportion of children with relapsed AML can be cured, even those with early relapse. Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%...
WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre studyMette Østergaard
Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
Br J Haematol 125:590-600. 2004..We conclude that WT1 expression by RQ-PCR may be employed as a tool to detect MRD in the majority of fusion transcript-negative AML patients...
Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trialsSverre O Lie
Department of Paediatrics, University Hospital, Rikshospitalet, Oslo, Norway
Br J Haematol 122:217-25. 2003..The overall outcome was improved by employing the previous toxic protocol with different timings, and through individualizing therapy according to the initial response of the patient...
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literatureLotte Abildgaard
Department of Paediatrics, Skejby Hospital, 8200, Aarhus N, Denmark
Ann Hematol 85:275-80. 2006..Further studies are needed to define the optimal regimen for treating myeloid leukaemia of DS...
Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapseJesper Stentoft
Department of Hematology, Aarhus University Hospital, Tage Hansens Gade 2, DK 8000 Aarhus C, Denmark
Leuk Res 30:389-95. 2006..This direct comparison between the two subgroups of CBF AMLs delineates clear biological differences and corroborates the value of RQ-PCR...
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trialFranco Locatelli
Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
Blood 105:410-9. 2005..Disease recurrence remains the major cause of treatment failure. Outcome of UD-HSCT recipients is comparable to that of children receiving transplants from an HLA-identical sibling...
Pediatric myelodysplastic syndromesCharlotte Marie Niemeyer
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Mathildenstrasse 1, 79106 Freiburg, Germany
Curr Treat Options Oncol 6:209-14. 2005..Unraveling some of the underlying genetic factors predisposing to MDS at a young age may give important insights into leukemogenesis in the elderly...
Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7Gabriela Kardos
Division of Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Mathildenstrasse 1, 79106 Freiburg, Germany
Blood 102:1997-2003. 2003..Recommendations for best treatment options for children with other chromosomal abnormalities or normal karyotype may have to await results of prospective clinical trials...
Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervalsHans Beier Ommen
The Laboratory of Immunohematology, Department of Haematology, Arhus University Hospital, Arhus, Denmark
Br J Haematol 141:782-91. 2008..In conclusion, CR1 WT1 expression is an independent prognostic factor in AML. According to our model, BM is superior for relapse prediction, but PB samples are useful when shorter sampling intervals are possible...
Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndromeAlice Norton
Blood 110:1077-9. 2007
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemiaMarco Tartaglia
Department of Pediatrics, Mount Sinai School of Medicine, New York, New York, USA
Nat Genet 34:148-50. 2003..Functional analyses documented that the two most common mutations in PTPN11 associated with JMML caused a gain of function...
Pain intensity and bioavailability of intramuscular asparaginase and a local anesthetic: a double-blinded studyBirgitte Klug Albertsen
Department of Pharmacology, The Bartholin Building, University of Aarhus, Denmark
Pediatr Blood Cancer 44:255-8. 2005..To evaluate if dissolution of asparaginase in lidocaine can relieve pain of an intramuscular injection in children without changes in bioavailability...
Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteriaEva Bergstraesser
Division of Pediatric Hematology and Oncology, University Children s Hospital Zurich, Zurich, Switzerland
Pediatr Blood Cancer 49:629-33. 2007..Classification schemas applied in other forms of leukemia are of little value, because in JMML therapy may result in divergent responses in solid organs compared to peripheral blood (PB)...
Contribution of multiparameter genetic analysis to the detection of genetic alterations in hematologic neoplasia. An evaluation of combining G-band analysis, spectral karyotyping, and multiplex reverse-transcription polymerase chain reaction (multiplex RTBirgitte S Preiss
Institute of Pathology-Laboratory of Molecular Pathology and Chromosome Laboratory, Odense University Hospital, Odense C. DK-5000, Denmark
Cancer Genet Cytogenet 165:1-8. 2006..Genetic techniques complement each other and selection of relevant and targeted primer kits for the multiplex RT-PCR assay is recommended...
Population-based study of cancer among carriers of a constitutional structural chromosomal rearrangementIben Bache
Wilhelm Johannsen Centre for Functional Genome Research, Department of Medical Biochemistry and Genetics, University of Copenhagen, Denmark
Genes Chromosomes Cancer 45:231-46. 2006..Molecular mapping of these breakpoints might provide new insight into cancer predisposition...
WT1 gene expression in children with Down syndrome and transient myeloproliferative disorderHenrik Hasle
Department of Pediatrics, Skejby Hospital, DK-8200 Aarhus N, Denmark
Leuk Res 30:543-6. 2006..The lack of normalization of WT1 level may be a predictor of leukemia development and WT1 expression may be an attractive marker for monitoring of minimal residual disease...
Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001Merete Stubkjaer Christensen
Department of Paediatrics, Skejby Hospital, Aarhus, Denmark
Br J Haematol 131:50-8. 2005..00). In conclusion, 3% of children with ALL died of TRD, with bacterial infections as the most common cause of death. Girls and Down syndrome patients had a higher risk of TRD. Infections still remain a major challenge in childhood ALL...
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative diseaseChristian P Kratz
University of California, Room HSE 302 Box 0519, San Francisco, CA 94143, USA
Blood 106:2183-5. 2005..This supports the need to characterize the spectrum of hematologic abnormalities in individuals with NS and to better define the impact of the PTPN11 lesion on the disease course in patients with NS/MPD and JMML...
Acute leukaemia in children with Down syndrome: a population-based Nordic studyBernward Zeller
Department of Paediatrics, National Hospital of Norway, N 0027 Oslo, Norway
Br J Haematol 128:797-804. 2005..The high proportion of female DS patients with AML is unexplained. The differing treatment results in AML versus ALL need further evaluation and represent a challenge for the coming years...
Multiplex reverse transcription polymerase chain reaction screening in acute myeloid leukemia detects cytogenetically unrevealed abnormalities of prognostic significanceMarianne Hutchings Hoffmann
Haematologica 90:984-6. 2005..In five patients, a cytogenetically unrevealed fusion gene of prognostic importance was detected, while the assay failed to detect one case of t(15;17)...
